NRNP 6550 Week 1 Discussion – Medicolegal Impacts on Health Promotion
NRNP 6550 Week 1 Discussion – Medicolegal Impacts on Health Promotion – Step-by-Step Guide
The first step before starting to write the NRNP 6550 Week 1 Discussion – Medicolegal Impacts on Health Promotion, it is essential to understand the requirements of the assignment. The first step is to read the assignment prompt carefully to identify the topic, the length and format requirements. You should go through the rubric provided so that you can understand what is needed to score the maximum points for each part of the assignment.
It is also important to identify the audience of the paper and its purpose so that it can help you determine the tone and style to use throughout. You can then create a timeline to help you complete each stage of the paper, such as conducting research, writing the paper, and revising it to avoid last-minute stress before the deadline. After identifying the formatting style to be applied to the paper, such as APA, you should review its use, such as writing citations and referencing the resources used. You should also review how to format the title page and the headings in the paper.
How to Research and Prepare for NRNP 6550 Week 1 Discussion – Medicolegal Impacts on Health Promotion
The next step in preparing for your paper is to conduct research and identify the best sources to use to support your arguments. Identify the list of keywords from your topic using different combinations. The first step is to visit the university library and search through its database using the important keywords related to your topic. You can also find books, peer-reviewed articles, and credible sources for your topic from PubMed, JSTOR, ScienceDirect, SpringerLink, and Google Scholar. Ensure that you select the references that have been published in the last few years and review each one for credibility. Ensure that you obtain the references in the required format, for example, in APA, to save time when creating the final reference list.
You can also group the references according to their themes that align with the outline of the paper. Go through each reference for its content and summarize the key concepts, arguments and findings for each source. You can write down your reflections on how each reference connects to the topic you are researching about. After the above steps, you can develop a strong thesis that is clear, concise and arguable. Next you should create a detailed outline of the paper so that it can help you to create headings and subheadings to be used in the paper. Ensure that you plan what point will go into each paragraph.
How to Write the Introduction for NRNP 6550 Week 1 Discussion – Medicolegal Impacts on Health Promotion
The introduction of the paper is the most crucial part as it helps to provide the context of your work, and will determine if the reader will be interested in reading through to the end. You should start with a hook, which will help capture the reader’s attention. You should contextualize the topic by offering the reader a concise overview of the topic you are writing about so that they may understand its importance. You should state what you aim to achieve with the paper. The last part of the introduction should be your thesis statement, which provides the main argument of the paper.
How to Write the Body for NRNP 6550 Week 1 Discussion – Medicolegal Impacts on Health Promotion
The body of the paper helps you to present your arguments and evidence to support your claims. You can use headings and subheadings developed in the paper’s outline to guide you on how to organize the body. Start each paragraph with a topic sentence to help the reader know what point you will be discussing in that paragraph. Support your claims using the evidence collected from the research, and ensure that you cite each source properly using in-text citations. You should analyze the evidence presented and explain its significance and how it connects to the thesis statement. You should maintain a logical flow between paragraphs by using transition words and a flow of ideas.
How to Write the In-text Citations for NRNP 6550 Week 1 Discussion – Medicolegal Impacts on Health Promotion
In-text citations help the reader to give credit to the authors of the references they have used in their works. All ideas that have been borrowed from references, any statistics and direct quotes must be referenced properly. The name and date of publication of the paper should be included when writing an in-text citation. For example, in APA, after stating the information, you can put an in-text citation after the end of the sentence, such as (Smith, 2021). If you are quoting directly from a source, include the page number in the citation, for example (Smith, 2021, p. 15). Remember to also include a corresponding reference list at the end of your paper that provides full details of each source cited in your text. An example paragraph highlighting the use of in-text citations is as below:
The integration of technology in nursing practice has significantly transformed patient care and improved health outcomes. According to Smith (2021), the use of electronic health records (EHRs) has streamlined communication among healthcare providers, allowing for more coordinated and efficient care delivery. Furthermore, Johnson and Brown (2020) highlight that telehealth services have expanded access to care, particularly for patients in rural areas, thereby reducing barriers to treatment.
How to Write the Conclusion for NRNP 6550 Week 1 Discussion – Medicolegal Impacts on Health Promotion
When writing the conclusion of the paper, start by restarting your thesis, which helps remind the reader what your paper is about. Summarize the key points of the paper, by restating them. Discuss the implications of your findings and your arguments. End with a call to action that leaves a lasting impact on the reader or recommendations.
How to Format the Reference List for NRNP 6550 Week 1 Discussion – Medicolegal Impacts on Health Promotion
The reference helps provide the reader with the complete details of the sources you cited in the paper. The reference list should start with the title “References” on a new page. It should be aligned center and bolded. The references should be organized in an ascending order alphabetically and each should have a hanging indent. If a source has no author, it should be alphabetized by the title of the work, ignoring any initial articles such as “A,” “An,” or “The.” If you have multiple works by the same author, list them in chronological order, starting with the earliest publication.
Each reference entry should include specific elements depending on the type of source. For books, include the author’s last name, first initial, publication year in parentheses, the title of the book in italics, the edition (if applicable), and the publisher’s name. For journal articles, include the author’s last name, first initial, publication year in parentheses, the title of the article (not italicized), the title of the journal in italics, the volume number in italics, the issue number in parentheses (if applicable), and the page range of the article. For online sources, include the DOI (Digital Object Identifier) or the URL at the end of the reference. An example reference list is as follows:
References
Johnson, L. M., & Brown, R. T. (2020). The role of telehealth in improving patient outcomes. Journal of Nursing Care Quality, 35(2), 123-130. https://doi.org/10.1097/NCQ.0000000000000456
Smith, J. A. (2021). The impact of technology on nursing practice. Health Press.
NRNP 6550 Week 1 Discussion – Medicolegal Impacts on Health Promotion Instructions
Medicolegal Impacts on Health Promotion
Vaccination can prevent the emergence and spread of disease. It is no surprise that it is a supported public health promotion issue. Many of the diseases targeted by vaccines are childhood diseases that impact the young; hence vaccination can prevent infants, children, and teens from potentially harmful diseases that can even be deadly.
But immunizations are not just for children. Protection from some childhood vaccines can wear off over time. Adults may also be at risk for vaccine-preventable disease due to age, job, lifestyle, travel, or other health conditions. Have a look at NRNP 6550 Week 2 Assignment – Assessing Diagnosing and Treating the iHuman Patient.
For this Discussion, review the immunization recommendations for patients across the lifespan. Reflect on how these recommendations might differ for patients who are immunocompromised or on immunosuppressive therapy. Consider how patient factors, such as age group and gender, might affect which immunizations are recommended by nurse practitioners for their patients.
To Prepare:
- Review the Learning Resources on medicolegal and health promotion considerations.
- Reflect on how medicolegal recommendations may impact health promotion strategies for the advanced practice nurse.
- By Day 3
- Post a comparison of the differences in immunizations that are recommended for patients ages 11–24, 25–64, and 65 years of age and older. Then, explain how these immunizations might impact patients who are immunocompromised or on immunosuppressive therapy. Be specific and provide examples by age group and gender.
- Note: For this Discussion, you are required to complete your initial post before you will be able to view and respond to your colleagues’ postings. Begin by clicking on the Reply button to complete your initial post. Remember, once you click on Post Reply, you cannot delete or edit your own posts and you cannot post anonymously. Please check your post carefully before clicking on Post Reply!
- Read a selection of your colleagues’ responses.
- By Day 6
- Respond to at least two of your colleagues on two different days and expand upon your colleagues’ posts by recommending which immunizations should be recommended to address immunocompromised or immune suppressed patients and explain why.
NRNP 6550 Week 1 Discussion – Medicolegal Impacts on Health Promotion Example
Patient Cases
Patients Aged 11-24 years
The immunizations recommended for patients aged 11-24 years are Tdap (Tetenus , Diphtheria, Pertussis), influenza, HPV (Human Papillomavirus), and Meningococcal Conjugate Vaccine (Kroger et al., 2023). One dose of Tdap is administered at 11 or 12 years and a Td booster is administered at intervals of 10 years. HPV is administered in two doses before the age of 15 years, and three doses are administered to individuals aged 15 years and above. The influenza vaccine is administered annually. The Meningococal conjugate vaccine is administered as one dose at the ages of 11 years or 12 years, and a booster dosage is administered at 16 years (Kroger et al., 2023).
Patients Aged 25-64 Years
For this age group, a Tdap or Td booster is administered every 10 years. They are administered with the influenza vaccine annually. Individuals who did not get vaccinated against HPV at 11-24 years can get the vaccine at this stage (cdc.gov, 2024). Patients aged 25- 64 years with a high risk of Hepatitis B can get the Hepatitis B vaccine. Pneumococcal vaccine is recommended for patients with a high risk of pneumococcal infections.
Patients Aged 65 Years and Older
For this age group, a Tdap or Td booster is administered every 10 years. They are also administered with the influenza vaccine annually (cdc.gov, 2024). Those with a high risk of Hepatitis B can get the Hepatitis B vaccine. This population is administered with two types of pneumococcal vaccines, the PPSV23 and PCV13. Individuals in this population are also administered with shingles vaccine; a dose of zoster vaccine line (ZVL) or two doses of Recombinant Zoster Vaccine (RZV) (cdc.gov, 2024).
Impact of Immunization on Immunocompromised and Immunosuppressed Patients
Immunocompromised and immunosuppressed such as those with human immunodeficiency virus (HIV) and cancer patients undergoing treatment may not respond effectively to vaccines (See, 2022). Their immune system is usually weakened hence they may not experience the full benefits of the vaccines. Live vaccines such as the live shingles vaccine (ZVL) should not be administered to immunocompromised and immunosuppressed patients due to an increased risk of experiencing full-blown ailment (cdc.gov, 2024). Older adults aged above 65 years have lower immunity levels compared to younger populations hence caution should be taken when administering them with live vaccines. They should be closely monitored for any vaccine-related complications following vaccine administration.
References
cdc.gov, (2024). Adult Immunization Schedule by Age. Recommendations for Ages 19 Years or Older, United States. https://www.cdc.gov/vaccines/hcp/imz-schedules/adult-age.html
See K. C. (2022). Vaccination for the Prevention of Infection among Immunocompromised Patients: A Concise Review of Recent Systematic Reviews. Vaccines, 10(5), 800. https://doi.org/10.3390/vaccines10050800Links to an external site.
Kroger, A. T. D. J., Bahta, L., Long, S., & Sanchez, P. (2023). General best practice guidelines for immunization: best practices guidance of the Advisory Committee on Immunization Practices (ACIP). https://stacks.cdc.gov/view/cdc/124166
NRNP 6550 Week 1 Discussion – Medicolegal Impacts on Health Promotion Example 2
Vaccines were first introduced in the late 18th century. It started with an unethical by todays standards, experiment on a 13 year old child (Plotkin, 2014). This was the introduction of the smallpox vaccine (Ginglen & Doyle, 2023). Since then vaccines have saved millions of lives and was one of the driving factors for the increase in life expectancy. Currently the vaccination schedules have differences based on age and at risk populations. We are going to focus on three age groups, 11-24, 25-64, and 65 and older, comparing and contrasting the recommendation of the CDC.
The vaccines recommended for the 11-24 age range, have arease of “catch up” if the vaccine was not administered prior to the age of 11. Hepatitis B, inactivated polio, influenza, measles, mumps, rubella, varicella, and hepatitis A are all recommended prior to age 11 but fall into this catch up phase. Tetanus diphtheria acellular pertussis (TDAP), COVID-19, human papillomavirus and meningococcal are recommended first doses. Haemophilus influenza, and pneumococcal conjugate are recommended for at risk population. It is important to note that the health care provider should work with the patient to determine the correct age and appropriate catch up schedules if necessary (CDC, 2024a).
In the second age range, 25-64 it is no longer about introducing new vaccines, more about making sure vaccines are up to date. The list of vaccines is Covid-19, Flu vaccine, hepatitis B, MMR, TDAP. At the Age of 50 the shingles and pneumococcal vaccines get added. The covid vaccine is 2 doses six months apart and the flu is annual or the newest seasonal version. It is important to note that the TDAP is a vaccine that needs to be administered every 10 years (CDC, 2024b).
The third age range is greater than 65 years of age. As our body ages, the human immune system gets weaker and the likelihood of infection increases (Ginglen & Doyle, 2023). The list of vaccines is COVID-19 two doses six months apart, the Flu vaccine annually, the Pneumococcal, shingles, respiratory syncytial virus (RSV), and the TDAP. This almost mirrors the vaccine schedule for the 25-64 age range, only adding two vaccines. Patients with advanced age are not the only population that needs additional vaccinations, immunocompromised patients have special considerations (CDC, 2024b).
In patients that are immunocompromised vaccination can help or even eliminate the acquiring of a disease. The population that is most likely to be immune compromised are cancer patients, transplant, and HIV patients (Cleveland Clinic, 2024). Special consideration should be taken, such as no live viruses, alternative dose schedule, and additional doses may be needed to elicit an immune response (Shoham et al., 2023). If a patient is exhibiting symptoms of illness it is important to weigh the option of delaying the administration of a vaccine. It is important for the patient and provider to work together for the best outcome and medical decisions for the patient.
References
CDC. (2024a). Child and Adolescent Immunization Schedule by Age Vaccines & Immunizations. https://www.cdc.gov/vaccines/hcp/imz-schedules/child-adolescent-age.html#cdc_generic_section_4-18-months-to-18-years
CDC. (2024b). Vaccines by Age. Vaccines & Immunizations. https://www.cdc.gov/vaccines/by-age/index.html#cdc_listing_res4-adults
Ginglen, J. G., & Doyle, M. Q. (2023). Immunization. Nih.gov; StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK459331/
Cleveland Clinic. (2024). If Your Immune System Is Compromised, Can You Get Vaccinated? Cleveland Clinic. https://health.clevelandclinic.org/can-immunocompromised-get-vaccines
Plotkin, S. (2014). History of vaccination. Proceedings of the National Academy of Sciences, 111(34), 12283–12287. https://doi.org/10.1073/pnas.1400472111
Shoham, S., Batista, C., Ben Amor, Y., Ergonul, O., Hassanain, M., Hotez, P., Kang, G., Kim, J. H., Lall, B., Larson, H. J., Naniche, D., Sheahan, T., Strub-Wourgaft, N., Sow, S. O., Wilder-Smith, A., Yadav, P., Bottazzi, M. E., & Lancet Commission on COVID-19 Vaccines and Therapeutics Task Force. (2023). Vaccines and therapeutics for immunocompromised patients with COVID-19. EClinicalMedicine, 59, 101965. https://doi.org/10.1016/j.eclinm.2023.101965